Professional Documents
Culture Documents
net/publication/264433999
CITATIONS READS
25 8,510
2 authors:
Some of the authors of this publication are also working on these related projects:
All content following this page was uploaded by Heather Kirkpatrick on 07 January 2015.
ABSTRACT
Key Words: PTSD, trauma, post-traumatic stress disorder, primary care, trauma and
stress-related disorders
*Based on a presentation given at The 34th Forum for Behavioral Science in Family
Medicine, Chicago, IL, September 19-22, 2013.
337
Epidemiology
The U.S. estimate of lifetime prevalence of PTSD in adults is 7.8%, with women
more at risk than men (20.4% vs. 8.2%) despite experiencing fewer traumas [2, 3].
Higher rates are also seen in African-Americans [4], Native Americans (14-16%)
[5], and in refugees from conflict-ridden areas of the world (9-60%) [6]. The types
of events experienced as the initial trauma vary widely and include combat,
personal assault, natural disasters, motor-vehicle accidents, rape, childhood
physical and sexual abuse, loss of loved ones [7], and medical crises such as
burns, cancer, and myocardial infarction [8, 9]. Risk factors can be considered
in three areas: Pre-trauma, Peri-trauma, and Post-trauma [10]. See Table 2.
Symptoms can occur at any age, and generally present within 3 months of
the trauma, but may occur years later. In Acute Stress Disorder (ASD), symptoms
are present for more than 3 days, but less than 1 month, after the trauma. In
contrast, diagnosis of PTSD requires symptoms persisting more than 1 month.
Symptom duration varies widely, with over 50% resolving within 3 months,
while many have persisting symptoms for longer than 1 year [1]. Symptoms
are often intermittent and relapse can occur. PTSD can be strongly associated
with physical illness complaints, particularly musculoskeletal, nervous, sensory,
cardio-respiratory, gastro-intestinal, and vague symptom presentations [11].
Etiology
PTSD is conceptualized as a failure of recovery caused in part by altered fear
learning; i.e., the failure to extinguish behavioral responses to stimuli associated
with the trauma. Following a trauma, the symptoms of PTSD are almost universal;
however, many people are able to eventually confront fearful stimuli such as
memories, reminders, or visual cues with a gradual decrease of fear. When this
decrease does not occur, people tend to develop cognitive and avoidance strategies
in an attempt to avoid distressing emotions. Subsequently, these strategies inter-
fere with the extinction of fear by limiting exposure to safe reminders. Alterations
in fear learning involve the hippocampus, amygdala, and prefrontal cortex. The
hippocampus appears to be involved in the ability to recall safe episodes when
faced with fearful stimuli. Research has shown that hippocampal volumes are
decreased in patients with PTSD, but this may be a risk factor rather than a sequella
[12]. There is also increasing attention to the role of the ventral medial prefrontal
cortex (VMPFC). Via its inhibitory control of the amygdala, the VMPFC may
allow the mind to “overwrite” the original fear, allowing safe episode memories
to become dominant [13]. There has also been extensive research regarding
aberrations in the hypothalamic-pituitary-adrenal axis function in patients with
PTSD; the dominant finding is that patients have increased levels of corticotrophin
releasing factor [14]. There is still little consensus in the literature regarding
the role of cortisol, with studies finding both higher and lower levels of cortisol
secretion in patients with PTSD [14]. Despite much investigation, there are no
reliable biological markers for at-risk patients [15]. Research continues in the
area of chemical prophylaxis (the prevention of PTSD pre- or immediately
post-trauma via interruption of fear learning), but controversy remains as study
findings are not consistent [16].
LITERATURE REVIEW
In your life, have you ever had any experience that was so frightening,
horrible, or upsetting that, in the past month you:
1. Have had nightmares about it or thought about it when you did not
want to? YES NO
2. Tried hard not to think about it or went out of your way to avoid situations
that reminded you of it? YES NO
tantrums are potential indicators that would justify further exploration. Children
and adolescents may also present with a sense of a foreshortened future.
Symptoms may often present somatically through complaints of headaches,
stomach aches, or other maladies [17, 20]. Collateral information attained from
parents and/or caregivers about behavioral changes can be especially useful.
Assessment is also improved by asking children directly about their experiences.
Psychotherapeutic Treatment
There are many effective psychotherapeutic treatments for individuals experi-
encing PTSD. Although the trauma-related therapies are generally effective at
symptom remission, they require adequate levels of psychological stability to be
successful. Patients with poor psychological stability can benefit from supportive,
ego-strengthening, or motivational treatment before beginning trauma-related
therapies [21].
The best evidence for remission of symptoms is for the trauma related therapies:
exposure therapy and cognitive behavioral therapy (CBT). Exposure therapy
involves graded exposure to situations causing the fear response, allowing the
individual to become desensitized to fear cues (habituation). The Institute of
Medicine’s (IOM) most recent review found exposure therapy to be effective in
significantly improving PTSD symptoms [22]. The IOM examined 23 randomized
trials, seven of which were found to be very methodologically sound. All seven
found clinically significant improvement in PTSD symptoms. CBT engages
the patient in challenging dysfunctional beliefs about the world or themselves
while simultaneously engaging the patient in more healthy behaviors such as
342 / KIRKPATRICK AND HELLER
Pharmacological Treatment
SUMMARY
In summary, PTSD is best characterized as a disorder of failed recovery.
It represents one of the few mental disorders in which the inciting event or
cause is generally known. Practitioners should recognize that avoidance is often
the “glue” that causes the disorder to endure, and treatments should be targeted
toward reduction of avoidance and titration of exposure to facilitate habituation.
Practitioners of primary care can educate patients that there are many effective
treatments for PTSD, and remission is very possible for many patients. We
are fortunate to be practicing during a time of explosive research on effective
344 / KIRKPATRICK AND HELLER
REFERENCES
29. Pae C, Lim H, Peindl K, Ajwani N, Serretti A, Patkar AA, et al. The atypical
antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress
disorder: A meta-analysis of randomized, double-blind, placebo-controlled clinical
trials. International Clinical Psychopharmacology 2008;23(1):1-8.
30. Davis LL, Davidson JRT, Ward LC, Bartolucci AA, Bowden C, Petty F. Divalproex in
the treatment of posttraumatic stress disorder: A randomized, double-blind, placebo-
controlled trial in a veteran population. Journal of Clinical Psychopharmacology
2008;28(1):84-88.
31. Braun P, Greenberg D, Dasberg H, Lerer B. Core symptoms of posttraumatic stress
disorder unimproved by alprazolam treatment. Journal of Clinical Psychiatry 1990;
51(6):236-238.
32. Hermos JA, Young MM, Lawler EV, Rosenbloom D, Fiore LD. Long-term, high-dose
benzodiazepine prescriptions in veteran patients with PTSD: Influence of preexisting
alcoholism and drug-abuse diagnoses. Journal of Trauma and Stress 2007;20(5):
909-914.
33. Hetrick SE, Purcell R, Garner B, Parslow RA. Combined pharmacotherapy and
psychological therapies for post traumatic stress disorder (PTSD). Cochrane Database
of Systematic Reviews 2010;2010(7), CD007316.
34. Foa EB, Davidson JRT, Frances AJ. Treatment of posttraumatic stress disorder
(expert consensus guideline series). Journal of Clinical Psychiatry 1999;60(suppl 16).
35. Management of Post-Traumatic Stress,Working Group. VA/DoD clinical practice
guideline for management of post-traumatic stress (version 2.0 ed.). Department of
Veterans Affairs and Department of Defense, 2010. Retrieved from http://www.
healthquality.va.gov/ptsd/CPGSummaryFINALMgmtofPTDFfinal021413.pdf
36. Bryant RA, Mastrodomenico JA, Hopwood S, Kenny LM, Cahill C, Kandris E,
et al. Augmenting cognitive behaviour therapy for post-traumatic stress disorder
with emotion tolerance training: A randomized controlled trial. Psychological
Medicine 2013;43:2153-2160.
37. Orsillo SM, Batten SV. Acceptance and commitment therapy in the treatment of
posttraumatic stress disorder. Behavior Modification 2005;29(1):95-129.
38. Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Martin SF, Yazar-Klosinski B,
et al. Durability of improvement in post-traumatic stress disorder symptoms and
absence of harmful effects or drug dependency after 3,4-methylenedioxymeth-
amphetamine-assisted psychotherapy: A prospective long-term follow-up study.
Journal of Psychopharmacology 2013;27(1):28-39.